GT Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by GT Biopharma, Inc. on August 14, 2026. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol GTBP. As of July 1, 2024, the company operates as a fully remote entity without a principal executive office.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
As of the record date (June 30, 2026), 44,338,573 shares were outstanding. Approximately 52.68% of eligible shares were present at the meeting, constituting a quorum. Key voting outcomes included:
- Board Elections: Four directors (Michael Breen, Charles J. Casamento, Hilary Kramer, David C. Mun-Gavin) were elected. Notably, significant numbers of votes were withheld for Casamento, Kramer, and Mun-Gavin (ranging from 1.73M to 1.79M), while Michael Breen received fewer withheld votes (447,942).
- Accountants: The appointment of Weinberg & Company, P.A. as independent accountants was ratified with 22,687,907 votes for and 423,433 against.
- Executive Compensation: The non-binding advisory vote on executive compensation was approved, though it faced significant opposition with 2,162,518 votes against compared to 6,057,507 for.
- Reverse Stock Split Authorization: Shareholders approved an amendment to the certificate of incorporation authorizing a reverse stock split at a ratio between 1-for-10 and 1-for-30, to be determined by the Board within one year. This proposal also included a reduction of authorized common stock to 25,000,000 shares. It received 18,077,466 votes for and 4,754,281 against.
- Equity Plan Amendments: Shareholders approved two amendments to the 2022 Omnibus Incentive Plan: (1) an increase of 3,500,000 shares available for awards, and (2) the adoption of an "evergreen" provision for automatic annual increases. Both proposals faced substantial opposition, with "Against" votes exceeding 2.7 million and 3.5 million respectively.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors. The primary strategic implication is the Board's new authority to execute a reverse stock split and reduce authorized share capital, which may be intended to address stock price or liquidity concerns, though the specific timing and ratio remain at the Board's discretion.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and implementation date once determined by the Board.
- Review the definitive proxy statement (Schedule 14A filed July 2, 2026) for detailed rationale behind the equity plan amendments and director elections.
- Monitor the company's stock price and trading volume to assess the impact of the approved reverse stock split authorization.
- Check subsequent filings for the actual reduction of authorized shares and the execution of the reverse split.